Study Shows Benefit of Multiple Assessments of MRD in Multiple Myeloma
A study affirmed the benefits of a multimodal approach in the assessment of minimal residual disease in multiple myeloma.
Multiple Myeloma
Likelihood of LVDD is Predictive of Carfilzomib-Induced Cardiovascular AEs in R/R Multiple Myeloma
In this retrospective study, researchers investigated whether assessing left ventricular diastolic function in patients receiving carfilzomib for relapsed or refractory multiple myeloma improved risk of cardiovascular adverse events.
FDA Approves Novel Therapy for Relapsed, Refractory Multiple Myeloma
Continued approval of Xpovio for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Prognostic Factors After Second Allogeneic HSCT in Patients With Relapsed Myelodysplastic Syndrome
The rate of 5-year overall survival in patients with myelodysplastic syndrome who underwent second allogeneic hematopoietic stem cell transplantation was 25.3%.
Fragmentation Pattern of Cell-Free DNA Can Reveal Cancer, Even at Early Stages
Machine learning algorithm detected 7 types of cancer in liquid biopsy and identified tissue of disease origin.
Solving the Obesity Paradox in Oncology
One potentially revolutionary hypothesis relates to the evolutionary processes involved in oncogenesis.
Worse Prognosis for Patients Treated With Upfront Radiation Therapy for Multiple Myeloma
Median overall survival was 3.6 years for patients who received upfront therapy and 4.2 years for patients who did not.
Darzalex Gets Approval for Additional Multiple Myeloma Indication
The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Emerging Pomalidomide-Based Triplet Therapies for Multiple Myeloma
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
Next post in General Oncology
